Hold HIMS by Aug 12, 2026.

[](https://preview.redd.it/hims-hers-hims-what-moves-hims-from-here-v0-snb0au8pr21h1.png?width=815&format=png&auto=webp&s=c45611c3a3c1da099cb3b5e721a61ed18ccc8866) Q1 2026 looked ugly on the headline and entirely different on the substance: this is the trough quarter of a deliberate strategic pivot, and Q1 captured **roughly one week of full branded Ozempic and Wegovy sales** after the late-March launch. The transition’s costs are all in the print. Almost none of the new revenue is. The numbers. Revenue: $608.1M, +4% YoY, missing $616.85M consensus. GAAP EPS: -$0.40 vs Street +$0.03. Net loss: $92.1M, swinging from +$49.5M last year. [](https://preview.redd.it/hims-hers-hims-what-moves-hims-from-here-v0-aeq7k6ctr21h1.png?width=840&format=png&auto=webp&s=bb352cad3000c019a228a3cc61502e13e9e146f2) …